ACCENDRA HEALTH INC/VA/

ACCENDRA HEALTH INC/VA/ (NYSE: ACH) Annual Report: A Comprehensive Review for Investors

ACCENDRA HEALTH INC/VA/ navigated a transformative fiscal year ending December 31, 2023, strategically divesting non-core assets and sharpening its focus on key healthcare segments. As a diversified provider of medical products and services, the company operates across several critical areas:

• Wound Care
• Urology
• Sleep Therapy
• Ostomy
• Home Respiratory Therapy
• Diabetes

ACCENDRA HEALTH INC/VA/ serves a broad customer base, including government programs like Medicare and Medicaid, and various commercial insurers. Often, it enters into "Capitation Agreements," where it receives a fixed payment per patient regardless of the services provided, ensuring more predictable revenue streams. The company maintains a broad geographic footprint, operating in the US (Virginia, Illinois, New York, Oregon, Pennsylvania, Massachusetts, Mississippi) and internationally (Australia, Belgium, Canada, Germany, India, Ireland, Japan, Mexico, Thailand).

Financial Performance: A Year of Strategic Re-alignment

For fiscal year 2023, ACCENDRA HEALTH INC/VA/ reported total revenue of $1.2 billion, a 5% decrease from the previous year. This decline primarily stemmed from the strategic divestiture of its "Products Healthcare Services" segment. However, excluding these divested operations, revenue from continuing operations achieved a healthy 3% organic growth, driven by strong demand in its Sleep Therapy and Urology segments.

The company reported a net loss of $15 million for the year, a shift from the $40 million net profit in the prior year. This loss largely resulted from $25 million in "Acquisition-Related Exit and Realignment Charges." These charges, associated with the divestiture, covered expenses such as employee severance, professional fees, and IT system integration. Additionally, the sale of the "Products Healthcare Services" segment led to a $10 million "Loss on Discontinued Operations." Despite these one-time costs, gross margins for continuing operations improved to 35% from 32%, signaling a healthier underlying business.

Management Discussion and Analysis (MD&A) Highlights

The most significant event of the year was the sale of the "Products Healthcare Services" segment in December 2023, which the company had classified as "held for sale" since April 2023. This strategic move aims to streamline operations, divest non-core assets, and enable ACCENDRA HEALTH INC/VA/ to focus resources on higher-growth, higher-margin product lines and integrated solutions within its remaining core segments like Urology and Sleep Therapy. Management believes this will enhance long-term profitability and shareholder value.

The MD&A detailed the results of operations, explaining the drivers behind the 5% revenue decrease (primarily the divestiture's impact) and the 3% organic growth in continuing operations. Management attributed the net loss to significant one-time charges related to the divestiture and discontinued operations, which they view as non-recurring. The MD&A highlighted the improvement in gross margins for continuing operations, from 32% to 35%, as a positive indicator of the underlying business's efficiency and product mix shift.

Regarding liquidity and capital resources, the MD&A emphasized the company's strong cash flow from operations ($60 million) and its diversified capital structure. This includes access to a revolving credit facility, which provides ample flexibility. The company uses interest rate swaps and a receivables purchase agreement as key strategies to manage financial risk and optimize working capital.

The MD&A also addressed a "Revision of Prior Period Error Correction Adjustment" for December 31, 2022. This adjustment resulted in a $5 million reduction in prior year net income related to revenue recognition. Management discussed the error's nature, its impact on prior period financial statements, and the strengthened internal controls implemented to prevent its recurrence, underscoring their commitment to financial reporting accuracy.

Financial Health

ACCENDRA HEALTH INC/VA/ maintains a diversified capital structure to fund its operations. As of December 31, 2023, the company reported total debt of $400 million, comprising:

• Term Loan A
• Term B Loans
• 6.625% Senior Notes
• 4.500% Senior Notes

Cash and cash equivalents stood at $75 million. The company also has access to a $100 million "Revolving Credit Facility," with $60 million currently undrawn, providing ample liquidity.

To manage interest rate volatility on its variable-rate debt, the company uses "Interest Rate Swaps." These swaps effectively convert a portion of its variable-rate debt to fixed rates, providing more predictable borrowing costs. Additionally, ACCENDRA HEALTH INC/VA/ employs a "Master Receivables Purchase Agreement" to optimize cash flow by selling certain accounts receivable to a third party, accelerating cash collection. Cash flow from operations for the year was a positive $60 million, demonstrating the company's ability to generate cash from its core business activities.

Key Risks and Challenges

Several factors pose potential risks to ACCENDRA HEALTH INC/VA/:

• Revenue Concentration: Approximately 45% of revenue comes from Medicare and State Medicaid Programs. Changes in government healthcare policies, reimbursement rates, or budget cuts could significantly impact profitability. Furthermore, reliance on a few large commercial insurers (the top 3 account for 20% of commercial revenue) creates vulnerability to contract renegotiations or terminations.
• Supplier Concentration: The company relies heavily on a limited number of key suppliers for critical components and finished goods. Supply chain disruptions, quality issues, or increased costs from these suppliers could impact operations and profitability.
• Integration and Execution Risk: While the divestiture is strategic, the associated restructuring and realignment activities carry execution risks, including potential disruptions to remaining operations or higher-than-anticipated costs.
• Financial Reporting Accuracy: The disclosure of a "Revision of Prior Period Error Correction Adjustment" for December 31, 2022, which reduced prior year net income by $5 million due to revenue recognition issues, could raise questions about the reliability of past financial statements and potentially impact investor confidence. Management stated that they have strengthened internal controls to prevent recurrence.
• Regulatory and Compliance Risks: Operating in the healthcare industry, the company must comply with extensive and complex federal, state, and international laws and regulations. Non-compliance could result in significant penalties, fines, or operational restrictions.
• Product Liability and Intellectual Property Risks: The company faces risks from product liability claims and the continuous need to protect its intellectual property while avoiding infringement on others' rights.

Competitive Position

ACCENDRA HEALTH INC/VA/ operates in a highly competitive healthcare market, facing competition from larger diversified healthcare companies and specialized niche players across its segments. The company differentiates itself through specialized product offerings, strong relationships with insurers, and a focus on patient outcomes. It maintains a strong market share in its core Wound Care and Sleep Therapy segments. Competition revolves around factors such as product innovation, quality, price, customer service, and the ability to adapt to evolving healthcare delivery models.

Future Outlook

Looking ahead to fiscal year 2024, management projects revenue from continuing operations to grow by 2-4%. This growth will be driven by new product introductions in Diabetes management and continued expansion in its Urology segment. They anticipate improved operating margins as the benefits of the divestiture and cost-saving initiatives materialize, targeting an operating margin of 8-10%. The company plans to invest $30 million in research and development to enhance its product pipeline, particularly in connected health solutions.

The company views the aging global population and the increasing shift towards home-based care as significant tailwinds for its business. However, ongoing regulatory scrutiny and pricing pressures in the healthcare industry remain constant challenges. The strategic focus on core, higher-growth segments is expected to position ACCENDRA HEALTH INC/VA/ for sustainable long-term growth and enhanced shareholder value.